Get the Stockscreener App
695.80
0.02%
0.62
Regeneron Pharmaceuticals Inc stock is traded at $695.80, with a volume of 452.31K.
It is up +0.02% in the last 24 hours and up +10.05% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
See More
Previous Close:
$695.18
Open:
$699.38
24h Volume:
452.31K
Relative Volume:
0.47
Market Cap:
$72.92B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
16.95
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
+6.78%
1M Performance:
+10.05%
6M Performance:
-7.22%
1Y Performance:
+24.58%
1-Day Range:
$691.00
$702.60
1-Week Range:
$637.80
$702.60
52-Week Range:
$541.00
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
695.50 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
489.85 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
879.02 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
181.43 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
285.70 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class ActionContact The Gross Law Firm - PR Newswire
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView
REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses - PR Newswire
(REGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses - PR Newswire
Regeneron Says Drug Approval Irrelevant In Antitrust Case - Law360
Regeneron on track to build in Saratoga - The Daily Gazette
Regeneron Pharmaceuticals (REGN) Q2 2026 Preview: EPS Est. $10.26, Reports July 30 - AlphaStreet
REGN DEADLINE: Levi & Korsinsky Reminds Regeneron - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire Inc.
Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
$REGN Lawsuit Notice: BFA Law Reminds Regeneron Investors - GlobeNewswire
14,700 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Orbimed Advisors LLC - MarketBeat
3,883 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Lombard Odier Asset Management Switzerland SA - MarketBeat
Renaissance Technologies LLC Has $51.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Family Manage LLC - MarketBeat
Entropy Technologies LP Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals (REGN) - simplywall.st
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lombard Odier Asset Management Europe Ltd Sells 3,124 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Sei Investments Co. Buys 18,403 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Arrowstreet Capital Limited Partnership Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of September 14, 2026 Deadline - ACCESS Newswire
GC Wealth Management RIA LLC Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Lido Advisors LLC - MarketBeat
Epoch Investment Partners Inc. Has $184.45 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock trades steadily as recent Eylea growth and pipeline advances frame valuation - AD HOC NEWS
Cannell & Spears LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron: I’m Not Concerned About The Declining ROIC And Operating Margins (NASDAQ:REGN) - Seeking Alpha
Regeneron Q2 Earnings Preview: Not Expecting MiraclesAt Least In The Short Term (REGN) - Seeking Alpha
TrumpRx.gov Savings Top $700 Million as Praluent Added at 60% DiscountNews and Statistics - IndexBox
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure - GlobeNewswire Inc.
The Scientist With 1,000 Patents Fueling a Drug Powerhouse - WSJ
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate FailureHBSS - PR Newswire
Regeneron stock trades near record levels as Eylea and Dupixent drive revenue growth - AD HOC NEWS
$REGN Fraud Notification: Regeneron Sued for Fraud Over - GlobeNewswire
Gibbs Wealth Management Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Bank of Nova Scotia - MarketBeat
Bessemer Group Inc. Sells 2,653 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Urged to Join Class Action Before September 14, 2026Contact Levi & Korsinsky - ACCESS Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. LawsuitREGN - Morningstar
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - Business Wire
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a - GlobeNewswire
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):